Alnylam Pharma Reports Positive Topline Results From Phase 2 Study Of Cemdisiran
WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals, Inc. (ALNY) reported topline results from the phase 2 study of cemdisiran, an investigational RNAi therapeutic targeting the C5 component of the